Nanoparticles for cancer targeting: Current and future directions

Current Drug Delivery

Volumn 13, Issue 8, 2016, Pages 1290-1302

  Swain, Suryakanta ^a   Sahu, Prafulla Kumar ^b   Beg, Sarwar ^c   Babu, Sitty Manohar ^a  

^a SIMS College of Pharmacy   (India)

^b Raghu College of Pharmacy   (India)

^c Roland Institute of Pharmaceutical Science   (India)

Author keywords

Cancer genetics; Carbon nanotubes; Folate receptor; Multifunctional nanoparticles; Quantum dots

Indexed keywords

CARBON NANOTUBE; COPPER NANOPARTICLE; DENDRIMER; FULLERENE DERIVATIVE; GOLD NANOPARTICLE; IRON OXIDE; LIPID; LIPOSOME; NANOBUBBLE; NANOCARRIER; NANOPARTICLE; NANOSHELL; QUANTUM DOT; SILVER NANOPARTICLE; SOLID LIPID NANOPARTICLE; ANTINEOPLASTIC AGENT;

CANCER THERAPY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; HUMAN; MICELLE; MICROENCAPSULATION; NANOMEDICINE; NANOTECHNOLOGY; PRIORITY JOURNAL; REVIEW; ANIMAL; CHEMISTRY; DRUG FORMULATION; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOPARTICLES; NEOPLASMS;

EID: 84995917338     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/1567201813666160713121122     Document Type: Review

References (147)

1. Yang, J.; Peters, I.; Williams, R.O. Inhaled Nanoparticles-A Current Review. Int. J. Pharm., 2008, 22 (356), 239-247
2. Sandhiya, S.; Dkhar, A. Emerging Trends of Nanomedicine-An Overview. Fundam. Clin. Pharmacol., 2009, 23 (3), 263-269
3. Krishna, R.; Mayer, D. Multidrug resistance (MDR) in cancer Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci., 2000, 11 (4), 265-283
4. Links, M.; Brown, R. Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs. Expert Rev. Mol. Med., 1999, 6(2), 1-21
5. Gottesman, M.; Hrycyna, P.; Schoenlein, V.; Pastan, I. Genetic analysis of the multidrug transporter. Annu. Rev. Genet., 1995, 29, 607-649
6. Davis, M.E.; Shin, M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov., 2008, 7(9), 771-782
7. Yon Ju-Nam, S.; Jamie, R. Manufactured Nanoparticles: An overview of their chemistry, interactions and potential environmental implications. Sci. Total Environ., 2008, 400 (1-3), 396-441
8. Sahoo, SK.; Labhasetwar, V. Nanotech approaches to drug delivery and imaging. Drug Discov. Today, 2003, 8(24), 1112-20
9. Peer, D.; Hong, O.C.; Farokhzad, R.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol., 2007, 2 (12), pp. 751-760
10. Malam, L.; Loizidou, M.; Seifalian, A.M. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci., 2009, 30(11), 592-599
11. Sutradhar, K.B.; Amin, M.L. Nanoemulsions: increasing possibilities in drug delivery. Eur. J. Nanomed., 2013, 5(2) 2, 97-110
12. Bharali, D.J.; Mousa, S.A. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. Pharmacol. Ther., 2010, 128(2), 324-335
13. Zhao, G.; Rodriguez, B.L. Molecular targeting of liposomal nanoparticles to tumor microenvironment. Int. J. Nanomedicine, 2013, 8, 61-71
14. Neil, SE. Nanotechnology for the Biologist. J. Leukoc. Biol., 2005, 78, 585-594
15. Grodzinski, P.; Silver, M.; Molnar, L.K. Nanotechnology for Cancer Diagnostics: Promises and Challenges. Expert Rev. Mol. Diagn., 2006, 6 (3), 307-318
16. Hofheinz, R.D.; Beyer, U.; Hochhaus, A. Liposomal Encapsulated Anti-cancer Drug. Anticancer Drugs, 2005, 16 (7), 691-707
17. Moghimi, S.M.; Szebeni, J. Stealth Liposomes and Long Circulating Nanoparticles: Critical Issues in Phar-macokinetics, Opsonization and Protein-Binding Proper-ties. Prog. Lipid Res., 2003, 42(6), 463-478
18. Sarker, D.K. Engineering of Nanoemulsions for Drug Delivery. Curr. Drug Deliv., 2005, 2, 297-310
19. Agnihotri, N.; Aminab-havi, T. M. Recent Advances on Chitosan based Micro and Nanoparticles in Drug Delivery. J. Control. Release, 2004, 100 (1), 5-28
20. Lee, L.J. Polymer Nano-engineering for Biomedical Applications. Ann. Biomed. Eng., 2006, 34(1) 75-88
21. Cherian, A.; Jain, S.K. Self-Assembled Carbohydrate stabilized Ceramic Nano-particles for the Parenteral Delivery of Insulin. Drug Dev. Ind. Pharm., 2006, 26 (4), 459-463
22. Davis, M.E.; Shin, D.M. Nanoparticle Therapeutics: An Emerging Treatment modality for Cancer. Nat. Rev. Drug Discov., 2008, 7, 771-782
23. Pelicano, H.; Martin, D.S.; Huang, P. Glycolysis Inhibition for Anticancer Treatment. Oncogene, 2006, 25, 4633-4646
24. Couvereur, P.; Dubernet, C.; Puisieux K. Controlled drug delivery with nanoparticles: current possibilities and future trends. Eur. J. Pharm. Biopharm., 1995, 41, 2-3
25. Ammoury, N.H.; Fessi, J.; Devissaguet, P.; Puisieux, F. In vitro release pattern of indomethacin from poly (d, l-lactide) nanocapsules. J. Pharm. Sci., 1990, 79, 763
26. Barrat, G.; Fattal, E.; Reis, C. Nanocapsule technology. Crit. Rev. Ther. Drug Carrier Syst., 2002, 19, 99-134
27. http://www.azonano.com/article.aspx?ArticleID=2159
28. Reddy, V.R. Gold Nanoparticles: Synthesis and Applications. Thieme e Journals, 2006, 11, 1791-1792
29. Das, R.; Nath, S.S.; Chakdar, D.; Gope G.; Bhattacharjee, S. Preparation of Silver Nanoparticles and their Characterization. Azo Nano J., 2009, 5(10) 2240
30. Wang, X.; Zhuang, J.; Peng, Q.; Li, Y. General Strategy for nanocrystal synthesis. Nature, 2005, 437, 121-124
31. Zhu, H.; Yin C. Novel Synthesis of Copper Nanoparticles: Influence of the Synthesis Conditions on the Particle Size. Nat. Nanotechnol., 2005, 16(2) 3079
32. Bharali, D.J.; Lucey, D.W.; Jayakumar, H.; Pudavar, H.E.; Prasad, P.N. Folate-receptor mediated delivery of InP quantum dots for bioimaging using confocal and two-photon microscopy. J. Am. Chem. Soc., 2005, 127, 11364-11371
33. Gao, X.; Cui, Y.; Levenson, R.M.; Chung, L.W.; Nie, S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol., 2004, 22, 969-976
34. Michalet, X.; Pinaud, F.F.; Bentolila, L.A.; Tsay, J.M.; Doose, S.; Li, J.J.; Sundaresan, G.; Wu, A.M.; Gambhir, S.S.; Weiss, S. Quantum dots for live cells, in vivo imaging, and diagnostics. Science, 2005, 307, 538-544
35. Howarth, M.; Takao, K.; Hayashi, Y.; Ting, A.Y. Targeting quantum dots to surface proteins in living cells with biotin ligase. Proc. Natl. Acad. Sci., 2005, 102, 7583-7588
36. Smith, A.M.; Dave, S.; Nie, S.; True, L.; Gao, X. Multicolor quantum dots for molecular diagnostics of cancer. Expert Rev. Mol. Diagn., 2006, 6, 231-244
37. Stroh, M.; Zimmer, J.P.; Duda, D.G.; Levchenko, T.S.; Cohen, K.S.; Brown, E.B.; Scadden, D.T.; Torchilin, V.P.; Bawendi, M.G.; Fukumura, D.; Jain, R.K. Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat. Med., 2005, 11, 678-682
38. Frangioni, J.V. In vivo near-infrared fluorescence imaging. Curr. Opin. Chem. Biol., 2003, 7, 626-634
39. Gao, J.; Chen, X.; Cheng, Z. Near Infrared quantum dots as optical probes for tumor imaging. Curr. Top. Med. Chem., 2010, 10, 1147-1157
40. Shubayev, V.I.; Pisanic, T.R., Jin, S. Magnetic nanoparticles for theragnostics. Adv. Drug Deliv. Rev., 2009, 61, 467-477
41. Sun, C.; Lee, J.S.; Zhang, M. Magnetic nanoparticles in MR imaging and drug delivery. Adv. Drug Deliv. Rev., 2008, 60, 1252-1265
42. Verdun, C.; Couvreur, P.; Vranckx, H.; Lenaerts, V.; Roland, M. Development of a nanoparticle controlled-release formulation for human use. J. Control. Release, 1986, 3, 205-210
43. Chen, T.J.; Cheng, T.H.; Chen, C.Y.; Hsu, S.C.; Cheng, T.L.; Liu, G.C.; Wang, Y.M. Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI. J. Biol. Inorg. Chem., 2009, 14, 253-260
44. Ho, K.M.; Li, P. Design and synthesis of novel magnetic core-shell polymeric particles. Langmuir, 2008, 24(5), 1801-1807
45. Zhang, Y.; Kohler, N.; Zhang, M. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials, 2002, 23, 1553-1561
46. Josephson, L.; Lewis, J.; Jacobs, P.; Hahn, P.F.; Stark, D.D. The effects of iron oxides on proton relaxivity. Magn. Reson. Imag., 1988, 6, 647-653
47. Wang, A.Z.; Bagalkot, V.; Vasilliou, C.C.; Gu, F.; Alexis, F.; Zhang, L.; Shaikh, M.; Yuet, K.; Cima, M.J.; Langer, R.; Kantoff, P.W.; Bander, N.H.; Jon, S.; Farokhzad, O.C. Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. Chem. Med. Chem., 2008, 3, 1311-1315
48. Bonnemain, B. Superparamagnetic agents in magnetic resonance imaging: Physicochemical characteristics and clinical applications. A Review. J. Drug Target, 1998, 6, 167-174
49. Reimer, P.; Tombach, B. Hepatic MRI with SPIO: Detection and characterization of focal liver lesions. Eur. Radiol., 1998, 8, 1198-1204
50. Kojima, C.; Kono, K.; Maruyama, K.; Takagishi, T. Synthesis of polyamidoaminedendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjug. Chem., 2000, 11, 910-917
51. Li, Y.; Cheng, Y.; Xu, T. Design, synthesis and potent pharmaceutical applications of glycodendrimers: a mini review. Curr. Drug Discov. Technol., 2007, 4, 246-254
52. Cheng, Y.; Wang, J.; Rao, T.; He, X.; Xu, T. Pharmaceutical applications of dendrimers: promising nanocarriers for drug delivery. Front Biosci., 2008, 13, 1447-1471
53. Bawarski, W.E.; Chidlowsky, E.; Bharali, D.J.; Mousa, S.A. Emerging nanopharmaceuticals. Nanomedicine, 2008, 4, 273-282
54. Lu, Y.; Low, P.S. Folate mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev., 2002, 54, 675-693
55. Anil, K.P.; Jolanta, F. Kukowska-Latallo, James, R.B. Jr. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv. Drug Deliv. Rev., 2005, 57, 2203-2214
56. Quintana, A.; Raczka, E.; Piehler, L.; Lee, I.; Myc, A.; Majoros, I.; Patri, A.K.; Thomas, T.; Mule, J.; Baker, J.R., Jr. Design and function of a dendrimer based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm. Res., 2002, 19, 1310-1316
57. Bawarski, W.E.; Chidlowsky, E.; Bharali, D.J.; Mousa, S.A.; Emerging nano pharmaceuticals. Nanomed: Nanotech. Biol. Med., 2008, 4, 273-282
58. Wang, X.; Wang, Y.; Chen, Z.; Shin, D.M. Advances of cancer therapy by nanotechnology. Cancer Res. Treat., 2009, 41(1), 1-11
59. Ferrari, M. Cancer nanotechnology: Opportunities and challenges. Nat. Rev. Cancer, 2005, 5, 161-171
60. Kataoka, K.; Harada, A.; Nagasaki, Y.; Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev., 2001, 43, 113-131
61. Nishiyama, N.; Kataoka, K.; Current state, achievements and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol. Ther., 2006, 112, 630-648
62. Wagner, E. Programmed drug delivery for tumor targeting. Expert Opin. Biol. The., 2007, 7, 587-593
63. Shi, W., Sahoo, Y., Swihert, M.P., Prasad, P.N. Gold nanoshells on polystyrene cores for control surface Plasmon resonance. Langmuir, 2005, 21, 1610-1617
64. West, J.L.; Halas, N.J. Engineered nanomaterialsforbiophotonics applications: improving sensing, imaging, and therapeutics. Annu. Rev. Biomed. Eng., 2003, 5, 285-292
65. Mansoori, G.A.; Mohazzabi, P.; McCormack, P.; Jabbari, S. Nanotechnology in cancer prevention, detection and treatment: bright future lies ahead. World Rev. Sci., Tech. Sust. Dev., 2007, 4(2/3), 226-257
66. Moghimi, S.M.; Hunter, A.C.; Murray, J.C. Long circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev., 2001, 53(2), 283-318
67. Lacerda, L.; Bianco, A.; Prato, M.; Kastarelos, K. Carbon nanotubes as nanomedicines: From toxicology to pharmacology. Adv. Drug Deliv. Rev., 2006, 58, 1460-1470
68. McDevitt, M.R.; Chattopadhyay, D.; Kappe, B.J.; Jaggi, J.S.; Schiffman, S.R.; Antczak, C.; Njardarson, J.T., Brentjeus, R.; Scheinberg, D.A. Tumor targeting with antibody functionalized radio-labelled carbon nanotubes. J. Nucl. Med., 2007, 48, 1180-1189
69. Mansoori, G.A.; Mohazzabi, P.; McCormack, P.; Jabbari, S. Nanotechnology in cancer prevention, detection and treatment: bright future lies ahead. World Rev. Sci., Tech. Sust. Dev., 2007, 4(2/3), 226-257
70. Wong, H.L.; Bendayan, R.; Rauth A.M.; Li, Y.; Wu, X.Y. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev., 2007, 59, 491-504
71. Jackson, L.S.; Lee, K. Microencapsulation and the Food Industry. Lebensm. Wiss. Technol., 1991, 24(4), 289-297
72. Klibanov, A.L. Microbubble contrast agents: targeted ultrasound imaging and ultrasound-assisted drug-delivery applications. Invest. Radiol., 2006, 41, 354-62
73. Ruan, S.; Qian, J.; Shen, S.; Chen, J.; Cun, X.; Zhu, J.; Jiang, X.; He, Q.; Gao, H. Non-invasive imaging of breast cancer using RGDyK functionalized fluorescent carbonaceous nanospheres. RSC Adv., 2015, 5, 25428-25436
74. Zheng, M.; Ruan, S.; Liu, S.; Sun, T.; Qu, D.; Zhao, H.; Xie, Z.; Gao, H.; Jing, X.; Sun, Z. Self-Targeting Fluorescent Carbon Dots for Diagnosis of Brain Cancer Cells. ACS Nano, 2015, 9(11), 11455-11461
75. Ruan, S.; Qian, J.; Shen, S.; Chen, J.; Zhu, J.; Jiang, X.; He, Q.; Yang, W.; Gao, H. Fluorescent Carbonaceous Nanodots for Noninvasive GliomaImaging after Angiopep-2 Decoration. Bioconjug. Chem., 2014, 25(12), 2252-2259
76. Chen, J.; Sun, H.; Wang, W.; Xu, W.; He, Q.; Shen, S.; Qian, J.; Gao, H. Polyethylene glycol modification decreases the cardiac toxicity of carbonaceous dots in mouse and zebrafish models. Acta Pharmacol. Sin., 2015, 36(11), 1349-1355
77. Yu, J.; Chu, X.; Hou, Y. Stimuli-responsive cancer therapy based on nanoparticles. Chem. Commun., 2014, 50, 11614-11630
78. Li, H.; Du, J.; Du, X.; Xu, C.; Sun, C.; Wang, H.; Cao, Z.; Yang, X.; Zhu, Y.; Nie, S.; Wang, J. Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy. Proc. Natl. Acad. Sci., 2016, 113(15), 4164-4169
79. Li, Y.Y.; Dong, H.Q.; Wang, K.; Shi, D.L.; Zhang, X.Z.; Zhuo, R.X. Stimulus-responsive polymeric nanoparticles for biomedical applications. Sci. China Chem., 2010, 53(3), 447-457
80. Gao, Z.; Kennedy, A.M.; Christensen, D.A.; Rapoport, N.Y. Drug loaded nano or microbubbles for combining ultrasonography and targeted chemotherapy. Ultrasonics, 2008, 48, 260-270
81. Gelperina, S.K.; Kisich, M.D.; Iseman Heifets, L. The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis. Am. J. Respir. Crit. Care Med., 2005, 172(12), 1487-1490
82. Bae, Y.; Nishiyama, N.; Fukushima, S.; Koyama, H.; Yasuhiro, M.; Kataoka, K. Preparation and Biological Characterization of Polymeric Micelle Drug Carriers with Intracellular pH-Triggered Drug Release Property: Tumor Permeability, Controlled Subcellular Drug Distribution, and Enhanced in vivo Antitumor Efficacy. Bioconjug. Chem., 2005, 16(1), 122-130
83. Physica, E. Quantum Dots in Biology and Medicine. Physica E Low Dimens. Syst. Nanostruct., 2004, 25(1), 1-12
84. Chithrani, B.D.; Stewart, J.; Allen, C.; Jaffray, D.A. Intracellullar Uptake, Transport, and Processing of Nanostructures in Cancer Cells. Nanomedicine, 2009, 5(2), 118-127
85. Day, E.S.; Morton, J.G.; West, J.L. Nanoparticles for Thermal Cancer Therapy. J. Biomech Eng., 2009, 131(7), 74001-74005
86. Ting, G.; Chang, C.H.; Wang, H.E. Cancer Nanotargeted Radiopharmaceutical for Tumor Imaging and Therapy. Anticancer Res., 2009, 29(10), 4107-4108
87. Thierry, B. Drug Nanocarriers and Functional Nanopar-ticles Application in Cancer Therapy. Curr. Drug Deliv., 2009, 6(4), 391-403
88. Santra, S.D.; Dutta, G.A.; Walter Moudgil, B.M. Fluorescent Nanoparticle Probes for Cancer Imaging. Technol. Cancer Res. Treat., 2005, 4(6), 593-602
89. Licha K.; Olbrich, C. Optical Imaging in Drug Discovery and Diagnostic Applications. Adv. Drug Deliv. Rev., 2005, 57(8), 1087-1108
90. Grodzinski, P.; Silver, M.; Molnar, L.K. Nanotechnology for Cancer Diagnostics: Promises and Challenges. Expert Rev. Mol. Diagn., 2006, 6(3), 307-318
91. Rao, J.; Dragulescu-Andrasi A.; Yao, H. Fluorescence Imaging in vivo: Recent Advances. Curr. Opin. Biotechnol., 2007, 18(1), 17-25
92. Huang, D.M.; Hung, Y.; Ko, B.S.; Hsu, S.C.; Chen, W.H.; Chien, C.L.; Tsai, C.P.; Kuo, C.T.; Kang, J.C.; Yang, C.S.; Mou, C.Y.; Chen, Y.C. Highly Efficient Cellular Labeling of Mesoporous Nanoparticles in Human Mesenchymal Stem Cells: Implication for Stem Cell Tracking. FASEB J., 2005, 19(14), 2014-16
93. Kim, J.; Lee, J.E.; Lee, S.H.; Yu, J.H.; Lee, J.H.; Park, T.G.; Hyecon, T. Design and Fabrication of a Multi-functional Polymer Nanomedical Platform for Simultaneous Cancer Targeted Imaging and Magnetically Guided Drug Delivery. Adv. Mater., 2008, 20, 478-483
94. Souhami, R.L.; Tannok, I.; Hohernberger, P.; Horiot, J.C. Oxford Text book of Oncology, Benjamin Lewin, Genes VIII, PrenticeHall, 2004, 889
95. Shah, K.; Jacobs, A.; Breakefield, X.O.; Weissleder, R. Molecular Imaging of Gene Therapy for Cancer. Gene Ther., 2004, 11, 1175-1187
96. Yamamoto, M.; Curiel, D.T. Cancer Gene Therapy. TCRT, 2005, 4, 315-330
97. Dickson, P.V.; Nathwani, A.C.; Davidoff, A.M. Delivery of Antiangiogenic Agents for Cancer Gene Therapy. TCRT, 2005, 4, 331-342
98. Vasir, J.K.; Labhasetwar, V. Targeted Drug Delivery in Cancer Therapy. TCRT, 2005, 4, 363-374
99. Govindan, S.V.; Griffiths, G.L.; Hansen, H.J. Cancer Therapy with Radiolabeled and Drug/Toxin-conjugated Antibodies. TCRT, 2005, 4, 375-392
100. Bethge, W.A.; Sandmaier, B.M. Targeted Cancer Therapy Using Radiolabeled Monoclonal Antibodies. TCRT, 2005, 4, 393-406
101. Lesniak, M.S. Novel Advances in Drug Delivery to Brain Cancer. TCRT, 2005, 4, 417-428
102. Sahoo, S.K.; Ma, W.; Labhasetwar, V. Efficacy of transferrinconjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int. J. Cancer, 2004, 112(2), 335-340
103. Zhao, G.; Rodriguez, B.L. Molecular targeting of liposomal nanoparticles to tumor microenvironment. Int. J. Nanomed., 2013, 8, 61-71
104. Pitsillides, C.M.; Joe, E.K.; Wei, X.; Anderson, R.R.; Lin, C.P. Selective cell targeting with light-absorbing microparticles and nanoparticles. Biophys. J., 2003, 84, 4023-4032
105. Tannock, I.F.; Lee, C.M.; Tunggal, J.K.; Cowan, D.S.M.; Egorin, M.J. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin. Cancer Res., 2002, 8(3), 878-884
106. Mousa S.A.; Bharali, D.J. Nanotechnology-based detection and targeted therapy in cancer: nano-bio paradigms and applications. Cancers, 2011, 3(3), 2888-2903
107. Krishna R.; Mayer, L.D. Multidrug resistance (MDR) in cancer Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci., 2000, 11(4), 265-283
108. Links, M.; Brown, R. Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs. Expert Rev. Mol. Med., 1999, 1-21
109. Gottesman, M.M.; Hrycyna, C.A.; Schoenlein, P.V.; Germann, U.A.; Pastan, I. Genetic analysis of the multidrug transporter. Annu. Rev. Genet., 1995, 29, 607-649
110. Davis, M.E.; Chen, Z.; Shin, D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov., 2008, 7(9), 771-782
111. Guo, X.; Szoka, F.C. Jr. Chemical approaches to triggerable lipid vesicles for drug and gene delivery. Acc. Chem. Res, 2003, 36(5), 335-341
112. Nie, S.Y.; Xing, G.J.; Kim Simons, J.W. Nanotechnology applications in cancer. Annu. Rev. Biomed. Eng., 2007, 9, 257-288
113. Cho, K.; Wang, X.; Nie, S.; Chen, Z.; Shin, D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res., 2008, 14 (5), 1310-1316
114. Yezhelyev, M.V.; Gao, X.; Xing, Y.; Al-Hajj, A.; Nie, S.; O’Regan, R.M. Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol., 2006, 7(8), 657-667
115. Duncan, R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer, 2006, 6(9), 688-701
116. Ferrari, M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer, 2005, 5(3), 161-171
117. LaVan D.A.; McGuire, T.; Langer, R. Small-scale systems for in vivo drug delivery. Nat. Biotechnol., 2003, 21(10), 1184-1191
118. Brigger, I.; Dubernet, C.; Couvreur, P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev., 2002, 54(5), 631-651
119. Jeon, S.I.; Lee, J.H.; Andrade, J.D.; De Gennes, P.G. Proteinsurface interactions in the presence of polyethylene oxide. I. Simplified theory. J. Colloid Interface Sci., 1991, 142(1), 149-158
120. Tallury, P.; Kar, S.; Bamrungsap, S.; Huang, Y.F.; Tan, W.; Santra, S. Ultra-small water-dispersible fluorescent chitosan nanoparticles: synthesis, characterization and specific targeting. Chem. Commun., 2009, 17, 2347-2349
121. Francis, M.F.; Cristea, M.; Winnik, F.M. Polymeric micelles for oral drug delivery: why and how. Pure Appl. Chem., 2004, 76(7-8) 1321-1335
122. Storm, G.; Belliot, S.O.; Daemen, T.; Lasic, D.D. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv. Drug Deliv. Rev., 1995, 17(1), 31-48
123. Mansoori, G.A.; Mohazzabi, P.P.; McCormack Jabbari, S. Nanotechnology in cancer prevention, detection and treatment: bright future lies ahead. Rev. Sci. Technol. Sustain. Devel., 2007, 4(2-3) 226-257
124. Sudimack J.; Lee, R.J. Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev., 2000, 41 (2), 147-162
125. Kukowska-Latallo, J.F.; Candido, K.A.; Cao, Z. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res., 2005, 65 (12), 5317-5324
126. Russell-Jones, G.; McTavish, K.; McEwan, J.; Thurmond, B. Increasing the tumoricidal activity of daunomycin-pHPMA conjugates using vitamin B12 as a targeting agent. J. Cancer Res. Updates, 2012, 1(2), 1-6
127. Zwicke, G.L.; Mansoori, G.A.; Jeffery, C.J. Utilizing the folate receptor for active targeting of cancer nanotherapeutics. Nano Rev., 2012, 3, 18496
128. Kawamoto, M.; Horibe, T.; Kohno, M.; Kawakami, K. A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells. BMC Cancer, 2011, 11, 359
129. Daniels, T.R.; Bernabeu, B.J.; Rodriguez, A. Transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim. Biophys. Acta, 2012, 1820 (3), 291-317
130. Patri, A.K.; Kukowska-Latallo, J.F.; Baker Jr., J.R. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv. Drug Deliv. Rev., 2005, 57(15), 2203-2214
131. Desai, N. Challenges in development of nanoparticle-based therapeutics. AAPS J., 2012, 14(2), 282-294
132. Brigger, I.; Dubernet, C.; Couvreur, P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev., 2002, 54(5) 631-651
133. Soma, C.E.; Dubernet, C.; Bentolila, D.; Benita, S.; Couvreur, P. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials, 2000, 21(1), 1-7
134. Amin, M.L. P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights, 2013, 7, 27-34
135. Matsuo, H.; Wakasugi, M.; Takanaga, H. Possibility of the reversal of multidrug resistance and the avoidance of side effects by liposomes modified with MRK-16, a monoclonal antibody to P glycoprotein. J. Control. Release., 2001, 77 (1-2), 77-86
136. Danson, S.; Ferry, D.; Alakhov, V. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br. J. Cancer, 2004, 90 (11), 2085-2091
137. Batrakova, E.V.; Dorodnych, T.Y.; Klinskii, E.Y. Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity. Br. J. Cancer, 1996, 74(10), 1545-1552
138. Goren, D.A.; Horowitz, T.; Tzemach, D.; Tarshish, M.; Zalipsky, S.; Gabizon, A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res., 2000, 6(5), 1949-1957
139. Huan, M.; Monty, L.; Tian, X.; Zongxi, Li.; Zhaoxia, Ji.; Jeffrey, I. Z.; Andre, E.N. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and p-glycoprotein sirna to overcome drug resistance in a cancer cell line. ACS Nano., 2010, 4 (8), 4539-4550
140. Che-Ming, J.H.; Liangfang, Z. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem. Pharmacolog., 2012, 8, 1104-1111
141. Hennessy, M.; Spiers, J.P. A primer on the mechanics of Pglycoprotein the multidrug transporter. Pharmacolog. Res., 2007, 55, 1-15
142. Adams, J.M.; Cory, S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene, 2007, 26, 1324-1337
143. Qiao, J.; Chen, S.; Jeanette, N.; Xiaowei, L.; Lin, L.; Dengli, Q.; Zhen-Gang, W.; Guozhang, Z.; Xingjie, L.; Hao, Y.; Baoquan, D. DNA origami as a carrier for circumvention of drug resistance. J. Am. Chem. Soc., 2012, 134, 13396-13403
144. Huan, M.; Wilson, X.; Mai, H.Z.; Min, X.; Tian, X.; Sijie, L.; Xiang, W.; Yang, Z.; Zhaoxia, J.; Jeffrey, I.; Zink; Andre, E.N. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano., 2013, 7 (2), 994-1005
145. Bradshaw, D.M.; Arceci, R.J. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J. Clin. Oncol., 1998, 16, 3674-3690
146. Zhang, L.; Radovic-Moreno, A.F.; Alexis, F.; Gu, F.X.; Basto, P.A.; Bagalkot, V. Codelivery of hydrophobic and hydrophilic drugs from nanoparticle aptamer bioconjugates. Chem. Med. Chem., 2007, 2, 1268-1271
147. Tardi, P.G.; Dos Santos, N.; Harasym, T.O.; Johnstone, S.A.; Zisman, N.; Tsang, A.W. Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo. Mol. Cancer Ther., 2009, 8, 2266-2275.